PeptiDream Inc.

Tokyo Stock Exchange 4587.T

PeptiDream Inc. Operating Income Margin for the year ending December 31, 2023: 23.59%

PeptiDream Inc. Operating Income Margin is 23.59% for the year ending December 31, 2023, a -29.46% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

PeptiDream Inc. Operating Income Margin for the year ending December 31, 2022 was 33.44%, a -29.11% change year over year.
PeptiDream Inc. Operating Income Margin for the year ending December 31, 2021 was 47.17%, a -21.21% change year over year.
PeptiDream Inc. Operating Income Margin for the year ending December 31, 2020 was 59.87%, a 170.01% change year over year.
PeptiDream Inc. Operating Income Margin for the year ending December 31, 2019 was -85.52%, a -272.41% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

Tokyo Stock Exchange: 4587.T

PeptiDream Inc.

CEO	Dr. Patrick Crawford Reid Ph.D.
IPO Date	June 12, 2013
Location	Japan
Headquarters	3-25-23 Tonomachi
Employees	745
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform for the development of peptides. It has a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was incorporated in 2006 and is headquartered in Kawasaki, Japan.

Key trends

Past 5 years